Search

News Effects of Metformin on the Cardiovascular System of Patients with Diabetes, but Also Without It

Diabetes mellitus (DM) is considered an independent risk factor for the development of ischemic heart disease (IHD). The prevalence of IHD is continuously increasing, making early detection of risk factors and their elimination crucial in reducing morbidity and mortality of all at-risk patients. Metformin is still recommended as the first-line drug for patients with type 2 DM by experts. In addition to its effects leading to a reduction in blood glucose levels, it also has a cardioprotective effect. Recently, studies focusing on primary and secondary cardiovascular prevention in patients with and without DM have been concentrating on it.

Source: Modern Treatment of Diabetes 5. 10. 2021

News Risk of Thromboembolism in ITP

Among other possible comorbidities in patients with ITP, thromboembolism represents one of the potential issues that require special attention.

Source: Immune Thrombocytopenia 7. 3. 2021

News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?

The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.

Source: Cardiovascular Continuum 21. 9. 2021

News Meta-analysis of Incidence of Infusion Reactions to Anti-EGFR Antibodies in Patients with mCRC

The application of antibodies against the epidermal growth factor receptor (EGFR), administered in slow infusions mainly as part of the treatment for metastatic colorectal cancer (mCRC), may be accompanied by infusion reactions or hypersensitivity reactions.

Source: Colorectal Cancer 20. 2. 2020

News AI Searches for New Antibiotics in Animal Venoms

The development of new antibiotics has stagnated for several decades for a variety of reasons. However, the use of AI could accelerate and reduce the cost of this process. Thanks to artificial intelligence, scientists are already discovering potential antibiotic sources in animal venoms.

Source: 24. 10. 2025

Články časopisu Sepsis mimics

Author of the article: Thomas Karvunidis, Martin Matějovič Source: Vnitřní lékařství | 6/2019 16. 8. 2019

News ESC 2022: Initiating Gliflozin in HFpEF During Hospitalization Can Benefit the Patient. This is Also Evidenced by Experience from the USA

Based on evidence from clinical studies, gliflozins are currently being introduced into practice for heart failure with preserved ejection fraction (HFpEF) as early as hospitalization. Sharing experiences is therefore very valuable. Several symposia at the ESC 2022 congress focused on the issue of introducing these drugs into HF treatment, some of which also included illustrative case studies. For example, the case of a patient with HFpEF from the USA demonstrated the early initiation of empagliflozin during hospitalization.

Source: Heart Failure 7. 10. 2022

News New Era in Migraine Therapy

Migraine is the most common type of primary headache. It affects about 10% of the world population. Recurring migraine attacks significantly reduce quality of life. Therefore, research in pharmacotherapy in recent years has logically focused on preventing attacks. The result is the latest possibility of biological treatment for migraines using monoclonal antibodies against CGRP receptors.

Source: Migraine 4. 5. 2020

News Current Recommendations of the American Society of Hematology for the Prevention of Thromboembolic Disease and Duration of Prophylaxis in Patients Undergoing Major Surgery

At the end of 2019, new recommendations were published by the American Society of Hematology (ASH) for the prevention of thromboembolic disease (VTE) in hospitalized patients. The new guidelines also addressed the duration of VTE prophylaxis in patients undergoing major surgical procedures.

Source: Prevention of Thrombosis in Surgery 4. 3. 2020

News Summary of Guidelines for the Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Pediatric Patients with Leukemia and Post Hematopoietic Stem Cell Transplantation

Invasive fungal diseases are a significant cause of morbidity and mortality among immunocompromised pediatric patients with leukemia and post-hematopoietic stem cell transplantation. During the 8th European Conference on Infections in Leukemia (ECIL-8) in 2020, the pediatric group reviewed and updated recommendations for the diagnosis, prevention, and treatment of invasive fungal infections in pediatric patients.

Source: Anti-Infectives 18. 11. 2021

News The Importance of Proper Protein and Calorie Intake in Critically Ill Patients –⁠ Insights from Recent Comparisons

The issue of nutrition, especially proteins, is a crucial aspect affecting the overall health and prognosis of critically ill patients. Two recent studies published in the journals Critical Care and Journal of Parenteral and Enteral Nutrition focused on nutrient intake.

Source: Parenteral Nutrition 14. 11. 2022

News Biological treatment of psoriatic arthritis in the 1st line –⁠ results of the SPIRIT-H2H study after 1 year of follow-up

The SPIRIT-H2H study compared the efficacy of ixekizumab and adalimumab, either as monotherapy or with concomitant methotrexate (MTX), in patients with psoriatic arthritis (PsA) who had not been previously treated with biologics. The results of the recent work presented below after one year of follow-up suggest that the efficacy of ixekizumab remains the same regardless of the use of MTX, while the efficacy of adalimumab increases in combination with MTX.

Source: Biological Treatment 3. 5. 2021

News Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?

A recently published study by a team of authors from several American institutions focused on comparing the efficacy and safety of the 5th generation cephalosporin ceftaroline with the standard of care in the treatment of sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA).

Source: Anti-Infectives 16. 9. 2022

News EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.

Source: Heart Failure 8. 3. 2022

News Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term safety of dupilumab in patients with this condition was evaluated in an open-label extension (OLE) of the LIBERTY AD study, the results of which were recently published.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 24. 1. 2023